Bayer Schering Pharma of Germany will provide its experimental PET radiotracer florbetaben to the Swiss-based biopharmaceutical company AC Immune to evaluate the effects of a vaccine being tested to treat patients with Alzheimer´s disease.
PET radiotracer enters Alzheimer trial
Bayer Schering Pharma of Germany will provide its experimental PET radiotracer florbetaben to the Swiss-based biopharmaceutical company AC Immune to evaluate the effects of a vaccine being tested to treat patients with Alzheimer´s disease. Phase II tests have demonstrated that florbetaben can image beta-amyloid deposition in the brain. In the phase I clinical trial of ACI-24, florbetaben may indicate the vaccine dose needed to produce a therapeutic effect.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.